Once-weekly somapacitan demonstrates similar one-year height gains compared to daily somatropin in a phase 2 trial in children with growth hormone deficiency
(WorldNews Africa)

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Once-weekly somapacitan demonstrates similar one-year height gains compared to daily somatropin in a phase 2 trial in children with growth hormone deficiency Vienna, Austria, 21 September 2019 - Novo Nordisk today announced that somapacitan, a novel growth hormone derivative in development as a once-weekly treatment option, demonstrated comparable efficacy, safety and tolerability to once-daily injections of Norditropin® (somatropin) after one year, with improved efficacy seen at the highest dose of somapacitan. The data, from the REAL 3 paediatric phase 2 trial in...